11. Release ceremony photo.JPG

 

 

 

On June 18, KyungDong Pharm held a launch ceremony for Litazin Tablets, Litamezin Tablets and Litamezin Extended-Release Tablets, DPP-4 inhibitor treatments for type 2 diabetes. Litazin contains linagliptin, a DPP-4 inhibitor with established cardiovascular safety. It can be used in patients with renal impairment, including chronic kidney disease, without dose adjustment or additional monitoring. Litamezin and Litamezin Extended-Release Tablets combine linagliptin and metformin in immediate-release and extended-release formulations, respectively. They improve dosing convenience for patients whose blood glucose is inadequately controlled with metformin alone, a first-line treatment for diabetes. To address the varied needs of patients with diabetes, who often have complications, Litamezin is available in three strengths—2.5/500 mg, 2.5/850 mg and 2.5/1000 mg—and Litamezin Extended-Release Tablets in two strengths—2.5/1000 mg and 5/1000 mg.